ReviewJournal of family medicine and primary care2021
A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma.
Review in Journal of family medicine and primary care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- A meta-analysis and trial sequential analysis of high intensity focused ultrasound ablation combined with transhepatic arterial chemotherapy and embolization for hepatoma.Frontiers in oncology · 2022Pooled it
- Construction and Validation of Prediction Model of Severe Abdominal Pain Post-Transarterial Chemoembolization in Patients with HBV-Associated Primary Liver Cancer.Computational and mathematical methods in medicine · 2022Trial
- Arterial and biliary complications after transarterial chemoembolization for hepatocellular carcinoma.World journal of clinical oncology · 2026Review
- Efficacy and safety of drug-eluting bead transarterial chemoembolization combined with hepatic arterial infusion chemotherapy in unresectable gastric cancer with liver metastasis.Therapeutic advances in medical oncology · 2026Article
- Article
- PhysMorph: A biomechanical and image-guided deep learning framework for real-time multi-modal liver image registration.Physics and imaging in radiation oncology · 2026Article
- Biomimetic nanoparticles for targeted therapy of liver disease.RSC pharmaceutics · 2025Review
- Efficacy and safety of donafenib plus transarterial chemoembolization and immunotherapy for hepatocellular carcinoma.World journal of gastrointestinal oncology · 2025Article
- Application of Nanotechnology in TACE Treatment of Liver Cancer.International journal of nanomedicine · 2025Review
- Machine learning-based decision support model for selecting intra-arterial therapies for unresectable hepatocellular carcinoma: A national real-world evidence-based study.British journal of cancer · 2024Article
- Racial/Ethnic Disparities and Immunotherapeutic Advances in the Treatment of Hepatocellular Carcinoma.Cancers · 2024Review
- DEB-TACE versus cTACE for unresectable HCC with B1-type bile duct invasion after successful biliary drainage: A propensity score matching analysis.Cancer medicine · 2024Article
- Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Current oncology (Toronto, Ont.) · 2024Review
- Prognostic value of preoperative serum ferritin in hepatocellular carcinoma patients undergoing transarterial chemoembolization.Molecular and clinical oncology · 2024Article
- Precision targeting in hepatocellular carcinoma: Exploring ligand-receptor mediated nanotherapy.World journal of hepatology · 2024Review
- Practical Considerations When Choosing Chemoembolization versus Radioembolization for Hepatocellular Carcinoma.Seminars in interventional radiology · 2024Review
- Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study.Anti-cancer agents in medicinal chemistry · 2024Article
- Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma.Frontiers in immunology · 2024Review
- Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia.Journal of hepatocellular carcinoma · 2024Article
- The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.Cancer biology & therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver cancer is one of the most ordinary reasons for death among cancers. Hepatocellular carcinoma (HCC) is the most common type of liver cancer. In spite of the fact that various remedial methods have been approved particularly the survival effects of the transcatheter arterial chemoembolization (TACE) method have been accomplished widely in the HCC treatment. By applying the TACE method correctly, good survival outcomes can be achieved without harmfully affecting the hepatic functions. Transarterial chemoembolization mixes the effect of avascular necrosis (AVN) with the effect of regional chemotherapy those are under the influence of arterial embolization. By knowing the fact that the metastases of liver cancer and also perfusion indices in hepatocellular carcinoma (HCC) are via hepatic arteries, doctors chose the TACE method for the treatment of liver cancer. On the other hand, in this method, the radiologists can easily convey antitumor remedies via the arteries. Anyway, medium-level HCC is a sensitive stage of the heterogeneous disease that many patients suffer from, so specialists must consider it as a hazardous syndrome. The TACE procedure could be applied just in cases that the liver function of patients is appropriate yet, the patient liver portal vein do not have any problems and the patients do not have ascites disorder. This review is aimed to figure out the evident advantages of TACE especially by a comprehensive view on the medium level HCC. Because of that this treatment method is suggested as a first-line remedy. At last, the future landscape of the initial factors of research in managing HCC disorders have been summarized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.